E-Scape Bio, a biopharmaceutical company developing small-molecule drugs to treat patients with genetically-defined neurodegenerative diseases, has reached an agreement with AbbVie to obtain worldwide rights to selective S1P5 receptor agonists for the treatment of lysosomal storage disorders impacting the central nervous system (CNS). These small molecule agonists are designed to reduce the synthesis of metabolites…
